Literature DB >> 15367216

TGF-beta induces Foxp3 + T-regulatory cells from CD4 + CD25 - precursors.

Shuang Fu1, Nan Zhang, Adam C Yopp, Dongmei Chen, Minwei Mao, Dan Chen, Haojiang Zhang, Yaozhong Ding, Jonathan S Bromberg.   

Abstract

CD4 + CD25 + regulatory T cells (Tregs) are potent suppressors, playing important roles in autoimmunity and transplantation tolerance. Understanding the signals necessary for the generation and expansion of Tregs is important for clinical cellular therapy, but only limited progress has been made. Recent reports suggest a role for TGF-beta in the generation of Tregs from CD4 + CD25 - precursors, but the mechanism remains unknown. Here, we demonstrate that TGF-beta2 triggers Foxp3 expression in CD4 + CD25 - precursors, and these Foxp3 + cells act like conventional Tregs. The generation of Foxp3 + Tregs requires stimulation of the T-cell receptor, the IL-2R and the TGF-beta receptor. More importantly, strong costimulation through CD28 prevents Foxp3 expression and suppressive function in an IL-4-dependent manner. Furthermore, TGF-beta-driven Tregs inhibit innate inflammatory responses to syngeneic transplanted pancreatic islets and enhance islet transplant survival. Thus, TGF-beta is a key regulator of the signaling pathways that initiate and maintain Foxp3 expression and suppressive function in CD4 + CD25 - precursors. TGF-beta and signaling through TGF-beta receptor, CD28 costimulation and IL-4 may be key components for the manipulation of Treg. The de novo generation of Foxp3 + cells from CD4 + cells has the potential to be used for treatment of autoimmune diseases and induction of transplant tolerance.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15367216     DOI: 10.1111/j.1600-6143.2004.00566.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  194 in total

1.  Regulatory T cells exhibit decreased proliferation but enhanced suppression after pulsing with sirolimus.

Authors:  K Singh; N Kozyr; L Stempora; A D Kirk; C P Larsen; B R Blazar; L S Kean
Journal:  Am J Transplant       Date:  2012-02-02       Impact factor: 8.086

2.  CD8+ Foxp3+ regulatory T cells are induced during graft-versus-host disease and mitigate disease severity.

Authors:  Amy J Beres; Dipica Haribhai; Alexandra C Chadwick; Patrick J Gonyo; Calvin B Williams; William R Drobyski
Journal:  J Immunol       Date:  2012-05-30       Impact factor: 5.422

Review 3.  The role of lymphocytes in the development and treatment of alopecia areata.

Authors:  Hongwei Guo; Yabin Cheng; Jerry Shapiro; Kevin McElwee
Journal:  Expert Rev Clin Immunol       Date:  2015-09-07       Impact factor: 4.473

Review 4.  Itch regulation of innate and adaptive immune responses in mice and humans.

Authors:  Natania S Field; Emily K Moser; Paula M Oliver
Journal:  J Leukoc Biol       Date:  2020-04-30       Impact factor: 4.962

Review 5.  Induced regulatory T cells: mechanisms of conversion and suppressive potential.

Authors:  Eefje M Dons; Giorgio Raimondi; David K C Cooper; Angus W Thomson
Journal:  Hum Immunol       Date:  2012-01-14       Impact factor: 2.850

Review 6.  Photodynamic therapy and anti-tumour immunity.

Authors:  Ana P Castano; Pawel Mroz; Michael R Hamblin
Journal:  Nat Rev Cancer       Date:  2006-07       Impact factor: 60.716

7.  Exosomal TGF-β1 is correlated with lymphatic metastasis of gastric cancers.

Authors:  Er-Yen Yen; Shi-Chuen Miaw; Jhang-Sian Yu; I-Rue Lai
Journal:  Am J Cancer Res       Date:  2017-11-01       Impact factor: 6.166

Review 8.  Pro- and anti-inflammatory cytokines in cutaneous leishmaniasis: a review.

Authors:  Nahid Maspi; Amir Abdoli; Fathemeh Ghaffarifar
Journal:  Pathog Glob Health       Date:  2016-09-23       Impact factor: 2.894

Review 9.  Differential T-cell receptor signals for T helper cell programming.

Authors:  Penelope A Morel
Journal:  Immunology       Date:  2018-05-25       Impact factor: 7.397

Review 10.  Harnessing the immune system to treat cancer.

Authors:  Nina Bhardwaj
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.